A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
This study is testing a new experimental drug called QTX3034 to see if it is safe and effective for treating certain solid tumor cancers. It specifically focuses on patients whose cancer has a specific genetic change known as a KRAS G12D mutation.
You may be eligible if you have advanced cancer with the KRAS G12D mutation and have already tried at least one other systemic treatment. Participants must be mobile and have cancer that can be clearly measured on medical scans.
You will receive either the new drug QTX3034 alone or in combination with an existing treatment called cetuximab. Doctors will monitor you closely to track how your body responds to the medicine and ensure your safety throughout the process.
The study is currently recruiting patients at medical centers in Los Angeles, Denver, and New Haven. Please speak with your oncology team to see if one of these locations is right for you.
- 1The trial is in the early stages, focused on checking safety and dosage.
- 2Participation requires a confirmed KRAS G12D genetic mutation found through lab testing.
- 3The study is currently open and actively looking for new participants.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.